ClinicalTrials.gg
CompletedNCT06010173Updated Jun 25, 2026Results posted

Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children

A Phase 3 interventional study of Gadopiclenol and Comparator (gadobutrol) in Lesion in Body Region and CNS Lesion, sponsored by Guerbet. Completed at 27 sites in Japan. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Sex
All
01

Study summary

GDX-44-014 - GDX-101 study was conducted in Japan including 2 cohorts (adult cohort for adult population and pediatric cohort for pediatric population), with different designs:

  • The adult cohort had a prospective, multi-center, randomized, double-blind, controlled, and cross-over design.
  • The pediatric cohort had a prospective, multi-center, non-randomized, open-label and single arm design.

The primary objective was to demonstrate the non-inferiority of gadopiclenol-enhanced MRI at 0.05 mmol/kg body weight (BW) compared to gadobutrol-enhanced MRI at 0.1 mmol/kg BW in terms of lesion visualization for adult patients referred for contrast-enhanced MRI of Central Nervous System (CNS) or Body regions.

Read the detailed description

Adult cohort:

The trial included a maximum of 5 visits and the record of patient's diagnosis as standard of truth:

  • One screening visit (V1) up to 7 days prior to the imaging visit (V2) (V1 could be done on the same day as V2 if all the inclusion/non-inclusion criteria were met).
  • Two sequential imaging visits (V2 and V4, minimum interval 2 days and up to 14 days): each visit consisted of gadopiclenol injection or comparator injection and MRI procedure.
  • Two safety visits (V3 and V5): 1 day after each injection and MRI examination.

Pediatric cohort:

The inclusions was divided into 4 age groups: patients from birth to 23 months of age inclusive, patients from 2 to 6 years, patients from 7 to 11 years and patients from 12 to 17 years. The recruitment in the 3 older groups of pediatric patients could be conducted in parallel with adult patients' enrolment. The decision to start the inclusion in the group of patients aged from birth to 23 months was taken by the Trial Safety Review Board (TSRB).

The trial included a maximum of 3 visits and the record of patient's diagnosis as standard of truth:

  • One screening visit (V1) up to 7 days prior to the imaging visit (V2) (V1 could be done on the same day as V2 if all the inclusion/non-inclusion criteria were met).
  • One imaging visit (V2) consisted of gadopiclenol injection and MRI procedure.
  • pharmacokinetics (PK) group: Blood sampling for PK started after gadopiclenol injection according to defined blood sampling schedule and took up to 8 hours.
  • One safety visit (V3): 1 day after gadopiclenol injection and MRI examination.

All Patients:

Images were assessed off-site in a centralized manner.

Pediatric group for pharmacokinetics (PK) analysis :

Up to 24 patients of the pediatric cohort would be included in gadopiclenol PK profile assessment.

The approach implemented for PK analyses allowed sparse blood sampling only and was selected to minimize the clinical burden to children.

All cohorts :

During the trial, the safety of the patients was monitored and assessed based on the reporting of adverse events (AEs), including vital signs, ECG for pediatric patients and clinical laboratory parameters (blood samples).

02

Conditions studied

  • Lesion in Body Region
  • CNS Lesion
03

In context

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria for all patients:

    1. All Patient presenting with known or suspected enhancing abnormality(ies) and/or lesion(s) in CNS or in at least one body region among head \& neck, thorax (e.g. breast), abdomen (e.g. liver, pancreas and kidney), pelvis (e.g. uterus, ovary and prostate) and musculoskeletal (e.g. extremities) based on a previous imaging procedure performed within 12 months prior to Form (ICF) signature.
    2. All If the patient was treated (either with radiation, surgery, , or other relevant treatments) between previous imaging evaluation and trial MRI, there should still be a high suspicion of remaining enhancing abnormality(ies) and/or lesion(s) based on available clinical information.
    3. All Patient able and willing to participate in the trial.
    4. All Patient affiliated to national health insurance according to local regulatory requirements.
  • Inclusion criteria for adult patients:

    1. Female or male adult patient having reached legal majority age of 18 years.
    2. Patient scheduled for a contrast-enhanced MRI examination of CNS or a Body region for clinical reasons and agreeing to have a second contrast-enhanced MRI examination for the purpose of the trial.
    3. Patient having read the information and having provided his/her consent to participate in writing by dating and signing the informed consent prior to any trial related procedure being conducted.
  • Inclusion criteria for pediatric patients:

    1. Female or male pediatric patient from birth to 17 years. For patients aged from birth to 27 days, only term newborn infants were eligible.

      Patients might not have reached the age of 18 years at the MRI examination.

    2. Patient whose parent(s) or legal guardian (where applicable) having read the information provided his/her/their consent to patient's participation in writing by dating and signing the informed consent prior to any trial related procedure being conducted.
    3. Patient with capacity of understanding who received age- and maturity-appropriate information and provided his/her assent to participate in the trial.
    4. PK Patient and his/her parent(s) or legal guardian (where applicable) having read the information and provided his/her consent in writing by dating and signing the Informed Consent form or respectively in the patient assent form their consent to participate in the PK analyses.

Exclusion Criteria:

  • Non-inclusion criteria for all patients:

    1. All Patient referred for contrast-enhanced cardiac MRI as primary examination (e.g. imaging protocol requiring stress or more than a single injection of gadolinium contrast agent) except for late-enhancement cardiac imaging.
    2. All Patient having received any medicinal product (IMP) within 7 days prior to trial entry or scheduled to receive any investigational treatment during the trial.
    3. All Patient presenting with any to MRI examinations.
    4. All Patient having received any contrast agent (for MRI or CT) within 3 days (or 7 days for patients \<1 year old) prior to trial product administration or scheduled to receive any contrast agent during the trial or within 24 hours after the last trial product administration (or 7 days after for patients \<1 year old).
    5. All Patient with anticipated, current, or past condition (medical, psychological, social or geographical) that would compromise the patient's safety or her/his ability to participate in the trial in the Investigator's opinion.
    6. All Female patient of with a positive urine pregnancy test done within 1 day prior to each contrast agent administration and not able / not willing to use highly effective birth-controlled method during the trial duration.

      Female had to have effective medically approved until the last trial visit, if of childbearing potential or with amenorrhea for less than 12 months or must be surgically sterilized or (> 2 years amenorrhea).

    7. All Patient unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits and/or unlikelihood of completing the trial.
    8. All Patient related to the Investigator or any other trial staff or relative directly involved in the trial conduct.
    9. All Patient with known contra-indication(s) to the use or with known sensitivity to one of the products under investigation or to other gadolinium based contrast agents (GBCAs) (such as , post contrast acute kidney injury).
  • Non-inclusion criteria for adult patients:

    1. Patient with acute disease that might rapidly evolve between the 2 MRI examinations
    2. Patient previously randomized in this trial.
    3. Patient expected/scheduled to have any treatment or medical procedure (e.g., chemotherapy, radiotherapy, biopsy, or surgery etc.) that might impact the aspects of the imaged lesions between the 2 MRI examinations. (Patients under and/or maintenance chemotherapy with a stable dose at the time of screening visit and throughout the trial could be included).
    4. Patient presenting an estimated (eGFR) \< 30 mL/min/1.73 m\^2 (based on Japanese coefficient-modified CKD-EPI (Chronic Kidney Disease - Epidemiology Collaboration) formula) assessed within 1 week prior to the first contrast agent administration.
  • Non-inclusion criteria for pediatric patients:

    1. Patient with previously attributed IMP number in this trial.
    2. Patient with known long syndrome.
    3. Patient presenting an estimated Glomerular Filtration Rate (eGFR) outside age-adjusted normal ranges (based on bedside Schwartz equation) assessed within one week prior to contrast agent administration.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With Gadobutrol

    Cross-over study. For each patient in this arm, he (she) performed the first contrast-enhanced MRI with gadopiclenol as contrast agent. After a washout period of 2-14 days, the patient performed the second contrast-enhanced MRI with gadobutrol as contrast agent. Gadopiclenol and gadobutrol were injected as a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. The injection rate should be identical for both products and might vary depending on scanned organ/region and age of patients.

    Drug: Gadopiclenol · Drug: Comparator (gadobutrol)

  • Experimental
    Adult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With Gadopiclenol

    Cross-over study. For each patient in this arm, he (she) performed the first contrast-enhanced MRI with gadobutrol as contrast agent. After a washout period of 2-14 days, the patient performed the second contrast-enhanced MRI with gadopiclenol as contrast agent. Gadobutrol and gadopiclenol were injected as a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. The injection rate should be identical for both products and might vary depending on scanned organ/region and age of patients.

    Drug: Gadopiclenol · Drug: Comparator (gadobutrol)

  • Experimental
    Pediatric cohort: One MRI With Gadopiclenol

    Pediatric patients underwent one MRI examination with gadopiclenol. Gadopiclenol was injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector.

    Drug: Gadopiclenol

Interventions

  • Dose/volume: Gadopiclenol administered was calculated based on patient's weight at the dose of 0.05 mmol/kg BW

    Also known as: Elucirem/Vueway

  • DrugComparator (gadobutrol)

    Dose/volume of comparator: Gadobutrol administered was calculated based on patient's weight at the dose of 0.1 mmol/kg BW.

    Also known as: Gadovist/Gadavist

06

What researchers measure

Primary outcomes

  1. Lesion Visualization on Paired Images: Border Delineation

    The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. Delineation of the lesion border was defined as the distinction of lesion from surrounding tissues, structures, or edema, and the detection of extent of the lesion. This criterion was assessed through the following scale: 1. = None 2. = Moderate 3. = Good 4. = Excellent: For this co-primary criterion, a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.

    Time frame: At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)

  2. Lesion Visualization on Paired Images: Internal Morphology

    The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. Internal morphology of the lesion included an identification of lesion architecture and the intra-lesion features such as necrosis, hemorrhage, and vascularity. This criterion was assessed through the following scale: 1. = Poor 2. = Moderate 3. = Good 4. = Excellent For this co-primary criterion "internal morphology", a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.

    Time frame: At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)

  3. Lesion Visualization on Paired Images: Degree of Contrast Enhancement

    The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. The criterion "degree of contrast enhancement" was a qualitative assessment (not based on signal intensity measurement) according to the following scale: 1. = No: no enhancement 2. = Moderate: weakly enhanced 3. = Good: clearly enhanced 4. = Excellent: clearly and brightly enhanced For each co-primary criterion, a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.

    Time frame: At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)

Secondary outcomes

  1. Pediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Border Delineation

    The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol as contrast agent. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.

    Time frame: At MRI exam, Day 1 (pediatric cohort)

  2. Pediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Internal Morphology

    The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.

    Time frame: At MRI exam, Day 1 (pediatric cohort)

  3. Pediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Degree of Contrast Enhancement

    The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.

    Time frame: At MRI exam, day 1 (pediatric cohort)

07

Results

Posted Jun 25, 2026

Participant flow

First MRI Examination
Participant flow — First MRI Examination
MilestoneAdult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With GadobutrolAdult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With GadopiclenolPediatric Cohort: One MRI With Gadopiclenol
Started10010040
Completed999840
Not completed120
Withdrew: Inclusion criteria not met100
Withdrew: Other reason020
Washout
Participant flow — Washout
MilestoneAdult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With GadobutrolAdult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With GadopiclenolPediatric Cohort: One MRI With Gadopiclenol
Started99980
Completed96960
Not completed320
Withdrew: Adverse event300
Withdrew: Withdrawal by subject010
Withdrew: Other reason010
Second MRI Examination
Participant flow — Second MRI Examination
MilestoneAdult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With GadobutrolAdult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With GadopiclenolPediatric Cohort: One MRI With Gadopiclenol
Started96960
Completed96960
Not completed000

Outcome measures

PrimaryLesion Visualization on Paired Images: Border Delineation

The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. Delineation of the lesion border was defined as the distinction of lesion from surrounding tissues, structures, or edema, and the detection of extent of the lesion. This criterion was assessed through the following scale: 1. = None 2. = Moderate 3. = Good 4. = Excellent: For this co-primary criterion, a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.

Time frame:
At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)
Reported as:
Least squares mean · score on a scale
Lesion Visualization on Paired Images: Border Delineation
score on a scalePatients With Gadopiclenol Paired ImagesPatients With Gadobutrol Paired Images
Border delineation - Reader A3.81 ± 0.043.75 ± 0.04
Border delineation - Reader B3.34 ± 0.053.24 ± 0.05
Border delineation - Reader C3.07 ± 0.053.00 ± 0.05
Statistical analysis
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.06 · 95% CI -0.02 to 0.15
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.09 · 95% CI 0.00 to 0.19
  • Patients With Gadopiclenol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.07 · 5% CI -0.02 to 0.16
PrimaryLesion Visualization on Paired Images: Internal Morphology

The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. Internal morphology of the lesion included an identification of lesion architecture and the intra-lesion features such as necrosis, hemorrhage, and vascularity. This criterion was assessed through the following scale: 1. = Poor 2. = Moderate 3. = Good 4. = Excellent For this co-primary criterion "internal morphology", a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.

Time frame:
At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)
Reported as:
Least squares mean · score on a scale
Lesion Visualization on Paired Images: Internal Morphology
score on a scalePatients With Gadopiclenol Paired ImagesPatients With Gadobutrol Paired Images
Internal morphology - Reader A3.71 ± 0.043.65 ± 0.04
Internal morphology - Reader B3.20 ± 0.073.17 ± 0.07
Internal morphology - Reader C3.24 ± 0.053.14 ± 0.05
Statistical analysis
  • Patients With Gadopiclenol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.06 · 5% CI -0.03 to 0.14
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.04 · 5% CI -0.07 to 0.14
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.10 · 95% CI 0.01 to 0.20
PrimaryLesion Visualization on Paired Images: Degree of Contrast Enhancement

The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. The criterion "degree of contrast enhancement" was a qualitative assessment (not based on signal intensity measurement) according to the following scale: 1. = No: no enhancement 2. = Moderate: weakly enhanced 3. = Good: clearly enhanced 4. = Excellent: clearly and brightly enhanced For each co-primary criterion, a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.

Time frame:
At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)
Reported as:
Least squares mean · score on a scale
Lesion Visualization on Paired Images: Degree of Contrast Enhancement
score on a scalePatients With Gadopiclenol Paired ImagesPatients With Gadobutrol Paired Images
Degree of contrast enhancement - Reader A3.70 ± 0.073.59 ± 0.07
Degree of contrast enhancement - Reader B3.18 ± 0.073.06 ± 0.07
Degree of contrast enhancement - Reader C3.04 ± 0.073.03 ± 0.07
Statistical analysis
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.12 · 95% CI 0.04 to 0.19
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.12 · 95% CI -0.01 to 0.25
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.02 · 95% CI -0.08 to 0.11
SecondaryPediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Border Delineation

The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol as contrast agent. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.

Time frame:
At MRI exam, Day 1 (pediatric cohort)
Reported as:
Least squares mean · mean of a score (on a scale) per patient
Pediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Border Delineation
mean of a score (on a scale) per patientPediatric Cohort: Patients With Paired ImagesPediatric Cohort: Patients With Pre-images
Border delineation - Reader A3.72 ± 0.131.88 ± 0.13
Border delineation - Reader B3.33 ± 0.132.57 ± 0.13
Border delineation - Reader C3.07 ± 0.142.34 ± 0.14
Statistical analysis
  • Pediatric Cohort: Patients With Paired Images vs Pediatric Cohort: Patients With Pre-images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 1.84 · 95% CI 1.45 to 2.23
  • Pediatric Cohort: Patients With Paired Images vs Pediatric Cohort: Patients With Pre-images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.76 · 95% CI 0.46 to 1.07
  • Pediatric Cohort: Patients With Paired Images vs Pediatric Cohort: Patients With Pre-images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 0.73 · 95% CI 0.40 to 1.07
SecondaryPediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Internal Morphology

The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.

Time frame:
At MRI exam, Day 1 (pediatric cohort)
Reported as:
Least squares mean · mean of a score (on a scale) per patient
Pediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Internal Morphology
mean of a score (on a scale) per patientPediatric Cohort: Patients With Paired ImagesPediatric Cohort: Patients With Pre-images
Internal morphology - Reader A3.76 ± 0.121.60 ± 0.12
Internal morphology - Reader B3.33 ± 0.142.26 ± 0.14
Internal morphology - Reader C3.15 ± 0.172.43 ± 0.17
Statistical analysis
  • Pediatric Cohort: Patients With Paired Images vs Pediatric Cohort: Patients With Pre-images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 2.16 · 95% CI 1.81 to 2.51
  • Pediatric Cohort: Patients With Paired Images vs Pediatric Cohort: Patients With Pre-images · t-test, 2 sided · p = <0.0001 · Median difference (net): 1.07 · 95% CI 0.73 to 1.42
  • Pediatric Cohort: Patients With Paired Images vs Pediatric Cohort: Patients With Pre-images · t-test, 2 sided · p = 0.0008 · Mean difference (net): 0.72 · 95% CI 0.30 to 1.14
SecondaryPediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Degree of Contrast Enhancement

The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.

Time frame:
At MRI exam, day 1 (pediatric cohort)
Reported as:
Least squares mean · Mean of a score (on a scale) per patient
Pediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Degree of Contrast Enhancement
Mean of a score (on a scale) per patientPediatric Cohort: Patients With Paired ImagesPediatric Cohort: Patients With Pre-images
Degree of contrast enhancement - Reader A3.68 ± 0.091.00 ± 0.09
Degree of contrast enhancement - Reader B3.30 ± 0.111.00 ± 0.11
Degree of contrast enhancement - Reader C3.27 ± 0.121.00 ± 0.12
Statistical analysis
  • Pediatric Cohort: Patients With Paired Images vs Pediatric Cohort: Patients With Pre-images · t-test, 2 sided · p = <0.0001 · Mean difference (net): 2.68 · 95% CI 2.42 to 2.94
  • Pediatric Cohort: Patients With Paired Images vs Pediatric Cohort: Patients With Pre-images · t-test, 2 sided · p = <0.0001 · Median difference (net): 2.30 · 95% CI 1.98 to 2.61
  • Pediatric Cohort: Patients With Paired Images vs Pediatric Cohort: Patients With Pre-images · t-test, 2 sided · p = <0.0001 · Median difference (net): 2.27 · 95% CI 1.93 to 2.60

Adverse events

Collected over For adult cohort, adverse event (AE) data were collected from informed consent signature to one day after the second MRI examination. For pediatric cohort, AE data were collected from informed consent signature to one day after the only MRI examination.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adult Cohort: TEAEs Occurring During and or After Gadopiclenol Administration0/195 (0%)1/195 (0.5%)26/195 (13.3%)
Adult Cohort: TEAEs Occurring During and or After Gadobutrol Administration0/194 (0%)3/194 (1.5%)24/194 (12.4%)
Pediatric Cohort: TEAEs Occurring During and or After Gadopiclenol Administration0/40 (0%)0/40 (0%)4/40 (10%)
Most frequent serious events
Most frequent serious events
EventAdult Cohort: TEAEs Occurring During and or After Gadopiclenol AdministrationAdult Cohort: TEAEs Occurring During and or After Gadobutrol AdministrationPediatric Cohort: TEAEs Occurring During and or After Gadopiclenol Administration
Animal BiteInjury, poisoning and procedural complications0/1951/1940/40
Intracranial Tumour HaemorrhageNervous system disorders0/1951/1940/40
IleusGastrointestinal disorders0/1951/1940/40
Febrile NeutropeniaBlood and lymphatic system disorders0/1951/1940/40
Cerebral InfarctionNervous system disorders1/1950/1940/40
Most frequent other events
Showing 10 of 46
Most frequent other events
EventAdult Cohort: TEAEs Occurring During and or After Gadopiclenol AdministrationAdult Cohort: TEAEs Occurring During and or After Gadobutrol AdministrationPediatric Cohort: TEAEs Occurring During and or After Gadopiclenol Administration
PyrexiaGeneral disorders0/1955/1940/40
LeukopeniaBlood and lymphatic system disorders0/1950/1941/40
NeutropeniaBlood and lymphatic system disorders0/1950/1941/40
ThrombocytopeniaBlood and lymphatic system disorders0/1950/1941/40
GastroenteritisInfections and infestations0/1950/1941/40
Blood creatinine increasedInvestigations0/1950/1941/40
HypochloraemiaMetabolism and nutrition disorders0/1950/1941/40
HyponatraemiaMetabolism and nutrition disorders0/1950/1941/40
HypertensionVascular disorders0/1950/1941/40
NauseaGastrointestinal disorders1/1952/1940/40

Baseline characteristics

The analysis was based on participants. Adult cohort: For the primary analysis, the analysis population was patients who had matching lesions on both Paired (combined unenhanced and contrast-enhanced) images performed with gadopiclenol and Paired images performed with gadobutrol. Per Protocol Set (PPS): 92 in the Arm 1 and 96 in the Arm 2. Pediatric cohort: 40 patients having matching lesions on both paired images and pre-contrast images with gadopiclenol as contrast agent (Full analysis Set)

Age, Continuous
Age, Continuous(years)Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With GadobutrolAdult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With GadopiclenolPediatric Cohort: One MRI With GadopiclenolTotal
Mean67.2 ± 11.963.8 ± 14.58.43 ± 5.2665.4 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With GadobutrolAdult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With GadopiclenolPediatric Cohort: One MRI With GadopiclenolTotal
Female384319100
Male545321128
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With GadobutrolAdult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With GadopiclenolPediatric Cohort: One MRI With GadopiclenolTotal
American Indian or Alaska Native0000
Asian929640228
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

27 sites
  • Meitetsu Hospital
    Aichi, 451-8511, Japan
  • Fukuoka University Hospital
    Fukuoka, 814-0180, Japan
  • Gifu University Hospital
    Gifu, 501-1194, Japan
  • Gunma University Hospital
    Gunma, 371-8511, Japan
  • Hiroshima City Hiroshima Citizens Hospital
    Hiroshima, 730-8518, Japan
  • Nakamura Memorial Hospital
    Hokkaido, 060-8570, Japan
  • National Hospital Organization Shikoku Medical Center for Children and Adults
    Kagawa, 765-8507, Japan
  • Kanagawa Children's Medical Center
    Kanagawa, 232-0066, Japan
  • Kobe City Medical Center General Hospital
    Kobe, 650-0047, Japan
  • University Hospital, Kyoto Prefectural University of Medicine
    Kyoto, 602-8566, Japan
  • Kyoto City Hospital
    Kyoto, 604-8845, Japan
  • Tohoku University Hospital
    Miyagi, 980-8574, Japan
  • Nara Medical University Hospital
    Nara, 634-8522, Japan
  • Kawasaki Medical School Hospital
    Okayama, 701-0192, Japan
  • Osaka Metropolitan University Hospital
    Osaka, 545-8586, Japan
  • Tominaga Hospital
    Osaka, 556-0017, Japan
  • Saitama Prefectural Children's Medical Center
    Saitama, 330-8777, Japan
  • Shin-Kuki General Hospital
    Saitama, 346-0021, Japan
  • Shizuoka General Hospital
    Shizuoka, 420-8527, Japan
  • Hamamatsu University Hospital
    Shizuoka, 431-3192, Japan
  • Jichi Medical University Hospital
    Tochigi, 329-0498, Japan
  • Tokyo Shinagawa Hospital
    Tokyo, 140-8522, Japan
  • Toho University Omori Medical Center
    Tokyo, 143-8541, Japan
  • National Center for Child Health and Development
    Tokyo, 157-8535, Japan
  • Tokyo Metropolitan Children's Medical Center
    Tokyo, 183-8561, Japan
  • Kurobe City Hospital
    Toyama, 938-8502, Japan
  • Yamaguchi University Hospital
    Yamaguchi, 755-8505, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in May 2025, 21 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 24, 2023
StartActual
Jul 21, 2023
Primary completionActual
May 6, 2025
CompletionActual
May 6, 2025
Results first posted
Jun 25, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06010173
Lead sponsor
Guerbet
Collaborators
Bracco Imaging S.p.A.
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Jul 21, 2023
Primary completion
May 6, 2025
Completion
May 6, 2025
Results posted
Jun 25, 2026
Last update
Jun 25, 2026

Study contacts

Toshiaki Taoka, MD
principal investigator · Nagoya University, JAPAN

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion